UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

GlobeNewswire
2025.11.06 13:33

新澤西州普林斯頓，2025 年 11 月 6 日（GLOBE NEWSWIRE）-- UroGen Pharma Ltd.（納斯達克：URGN），一家致力於開發和商業化治療尿路上皮癌和特殊癌症的創新解決方案的生物技術公司，今天宣佈其正在進行的第三階段 UTOPIA 試驗的強勁初步結果

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.